Literature DB >> 27314096

Polycomb and lung cancer: When the dosage makes the (kind of) poison.

Gaetano Gargiulo1, Elisabetta Citterio1, Michela Serresi1.   

Abstract

The Polycomb transcriptional repressors regulate normal tissue homeostasis and their function is often hijacked during oncogenesis. We recently uncovered the Polycomb repressive complex-2 (PRC2) genes Ezh2 and Eed as oncogenotype-dependent cancer genes. Notably, within the same oncogenotype, PRC2 dosage modulates lung tumor homeostasis and critically impacts non-tumor tissue function.

Entities:  

Keywords:  Epigenetics; Ezh2; Kras; Lung Cancer; Polycomb; inflammation; p53

Year:  2016        PMID： 27314096      PMCID： PMC4909420          DOI： 10.1080/23723556.2016.1152345

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation.

Authors:  Nathan D Montgomery; Della Yee; Andrew Chen; Sundeep Kalantry; Stormy J Chamberlain; Arie P Otte; Terry Magnuson
Journal:  Curr Biol       Date:  2005-05-24       Impact factor: 10.834

Review 2.  Context-dependent actions of Polycomb repressors in cancer.

Authors:  M Koppens; M van Lohuizen
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

Review 3.  PRC2 mediated H3K27 methylations in cellular identity and cancer.

Authors:  Eric Conway; Evan Healy; Adrian P Bracken
Journal:  Curr Opin Cell Biol       Date:  2015-11-11       Impact factor: 8.382

Review 4.  Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer.

Authors:  Diletta Di Mitri; Andrea Alimonti
Journal:  Trends Cell Biol       Date:  2015-11-09       Impact factor: 20.808

5.  Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer.

Authors:  Michela Serresi; Gaetano Gargiulo; Natalie Proost; Bjorn Siteur; Matteo Cesaroni; Martijn Koppens; Huafeng Xie; Kate D Sutherland; Danielle Hulsman; Elisabetta Citterio; Stuart Orkin; Anton Berns; Maarten van Lohuizen
Journal:  Cancer Cell       Date:  2016-01-11       Impact factor: 31.743

Review 6.  Macrophage activation syndrome.

Authors:  Angelo Ravelli
Journal:  Curr Opin Rheumatol       Date:  2002-09       Impact factor: 5.006

Review 7.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 8.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

9.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

10.  Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis.

Authors:  Michel Wassef; Veronica Rodilla; Aurélie Teissandier; Bruno Zeitouni; Nadege Gruel; Benjamin Sadacca; Marie Irondelle; Margaux Charruel; Bertrand Ducos; Audrey Michaud; Matthieu Caron; Elisabetta Marangoni; Philippe Chavrier; Christophe Le Tourneau; Maud Kamal; Eric Pasmant; Michel Vidaud; Nicolas Servant; Fabien Reyal; Dider Meseure; Anne Vincent-Salomon; Silvia Fre; Raphaël Margueron
Journal:  Genes Dev       Date:  2015-12-04       Impact factor: 11.361
  10 in total
  1 in total

1.  Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

Authors:  Michela Serresi; Bjorn Siteur; Danielle Hulsman; Carlos Company; Matthias J Schmitt; Cor Lieftink; Ben Morris; Matteo Cesaroni; Natalie Proost; Roderick L Beijersbergen; Maarten van Lohuizen; Gaetano Gargiulo
Journal:  J Exp Med       Date:  2018-11-28       Impact factor: 14.307
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.